Major Depressive Disorder

Recent research from the National Psoriasis Foundation (NPF) found that 1 in 3 individuals living with psoriatic conditions experience depression.

The results show 88.6% of participants had medium to high range emotion exhaustion, while 82.8% exhibited medium to high range depersonalization and 19.6% of patients had low to medium range personal accomplishment.

The meta-analysis showed an increased odds ratio of developing postpartum depression when the maternal family had a history of psychiatric disorders.

Dextromethorphan HBr-bupropion HCI (Auvelity) is developed by Axsome Therapeutics.

Postpartum depression rates have increased since the COVID-19 pandemic.

Alcohol, stress, drug use, and not seeking help are all risk factors for chronic depression.

Mixed feature depression can be difficult to diagnose because the symptoms can be similar to other psychiatric disorders.

There remains a need for more research into the connection between grief and depression following a death.

Borderline personality disorder remains one of the most difficult to understand conditions in psychiatry.

Esketamine is seen as a major breakthrough in finding more treatments for depression.

Dr. Shear talked about the similarities and differences between depression and grief and the importance of recognizing both.

Dr. Levine talks with Dr. Lisa Harding about how clinicians can best improve patient care in psychiatry.

The prevalence of suicidal was 10.9% in studies that included child-reported outcomes for child only and 10.4% for child and parent combined.

The association with depressive symptoms was greater when race, ancestry, or national origins among Hispanic or Latino participants was the main reason for discrimination.

Patients with psoriatic arthritis (PsA) who have elevated interleukin-23 (IL-23) levels have been linked to higher rates of depression, anxiety, and disease activity.

The investigators found the overall age-standardized prevalence of depression based on the CIDI-SF scale was 5.7%, significantly higher than the self-reported rate of 0.5%.

A survey of 10,325 individuals shows 30.2% of healthcare workers likely meet the diagnostic criteria for clinical depression.

During follow-up, 2.6% of the patients were diagnosed with depression, while 32.1% were treated with antidepressants.

The efficacy of treating insomnia sustained throughout the 24-week postintervention follow-up period for the electroacupuncture treatment group.

Patients with Crohn’s disease subtype, females, pediatric-onset IBD, young adult patients with IBD, and patients with short-duration IBD were all at a higher risk for suicide.

There were several risk factors for generalized anxiety disorder including being a health care worker, having a chronic illness, and fear of contracting COVID-19.

Those with a first-degree female relative with PPD history were more than 2.5 times likelier to have PPD.

Today in a late-breaking abstract from SLEEP 2022, data showed the reduction of slow wave activity in unmedicated adolescents with depression.

The majority of treatment emergent adverse events were mild to moderate in severity.

AXS-05 also showed superiority to placebo in safety.

With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.

The lead author of treatment recommendations weighs in on their current use and future research.

New phase 3 data presented at APA 2022 support the agent as an adjunctive in older patients without benefit from monotherapy antidepressant medication.

Anita Clayton, MD, reviews the available phase 2 and 3 clinical data for the novel, once-daily oral investigative drug.

Dr. Carolyn Rowley talks about the Cayenne Wellness Center's mental health initiative for individuals with sickle cell disease and shares the story of one of her first patients.